TEL AVIV, Israel, Feb. 10, 2022 /PRNewswire/ -- Chemomab
Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage
biotechnology company focused on the discovery and development of
innovative therapeutics for fibrotic and inflammatory diseases with
high unmet need, today announced that it will present a company
overview at the Aegis Capital Corp. Virtual Conference on
February 24, 2022, at 9:00 am ET.
To access the event: click
https://us02web.zoom.us/j/86168915443
A copy of Chemomab's presentation will also be available on
Chemomab's website at https://investors.chemomab.com/ starting
on February 24, 2022.
For additional information on accessing the Chemomab
presentation, click on Aegis Virtual Conference Calendar.
About Chemomab Therapeutics Ltd.
Chemomab is a clinical-stage biotechnology company focusing
on the discovery and development of innovative therapeutics for
fibrotic and inflammatory diseases with high unmet need. Based on
the unique and pivotal role of the soluble protein CCL24 in
promoting fibrosis and inflammation, Chemomab developed CM-101, a
monoclonal antibody designed to bind and block CCL24 activity.
CM-101 has demonstrated the potential to treat multiple severe and
life-threatening fibrotic and inflammatory diseases. It is
currently in two Phase 2 safety and efficacy trials—one in patients
with primary sclerosing cholangitis and the second in patients with
liver fibrosis, with a third Phase 2 trial in systemic sclerosis
expected to begin early in 2022. For more information on Chemomab,
visit chemomab.com.
Contacts:
Investor
Relations:
Irina
Koffler
LifeSci Advisors,
LLC
Phone:
+1-917-734-7387
ir@chemomab.com
Media:
Barbara Lindheim
Chemomab Therapeutics
Consulting Vice President
Investor & Public Relations, Strategic Communications
Phone: +1-917-355-9234
barbara@chemomab.com
View original
content:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-present-at-aegis-virtual-conference-301479592.html
SOURCE Chemomab Therapeutics Ltd